Research Study

A Randomized Phase II Study of Sequencing Abiraterone Acetate and Enzalutamide in Metastatic Castration-Resistant Prostate Cancer
Principal Investigator 
Kim Nguyen Chi

Overview

Body Locations and Systems 
Prostate Cancer
ClinicalTrials.gov# 
NCT02125357
Status 
Closed to Recruitment
Study Start/End 
Jun 30, 2014 to Oct 1, 2017
Locations 
Vancouver General Hospital
Name/Title 
Maureen Palmer, Research Coordinator
Phone 
604-875-5003
Purpose of Study 

This study is being offered to patients who have castrate-resistant (also known as hormone-refractory) prostate cancer. The cancer has metastasized or spread outside the prostate area to other parts of the body.

The purpose of this study is to evaluate the effects of sequencing hormonal therapies (abiraterone acetate and enzalutamide) and to assess treatment efficacy of these two agents.

Eligibility 

Visit ClinicalTrials.gov for more information.

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician.